Picture EBD Group ChinaBio Partnering Forum 2022 650x100
Document › Details

bioMérieux S.A.. (4/19/18). "Press Release: bioMérieux – First-Quarter 2018 Business Review".

Organisations Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
  Organisation 2 Astute Medical Inc.
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 immunoassay (diagnostics, antibody-antigen-test)
Index term Index term Astute Medical–Mérieux: investment, 201804 acquisition $90m in cash by bioMérieux
Person Person Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Strong sales dynamic in first-quarter 2018, with sales up 12.5% at constant exchange rates and scope of consolidation:

>> €587 million in sales
>> Up 3.4% as reported

> Growth driven by molecular biology in the context of an intense flu season in the United States, and by buoyant business in the Asia-Pacific region

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “In the first quarter, bioMérieux delivered a sound commercial performance. The recent acquisition of Astute Medical will strengthen bioMérieux’s commitment and position in immunoassays and is a perfect fit with our strategy of developing high medical value tests in order to improve patient care.”

Download [ FULL RELEASE at ]

Record changed: 2018-05-28


Picture Berlin Partner Voices from Berlin-Brandenburg Georg Duda 650x200px

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BIO-Europe 2022 Leipzig 650x300px

» top